Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 67 references it cites were found in a registry or an index; 11 of the 77 sources its claims cite were checked for support.

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art

Open access

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective in improving glycaemic control either as monotherapy or in combination with other hypoglycaemic drugs, and have low incidence of side effects, such as hypoglycaemia, nausea and weight gain, thus increasing patients' adherence to therapy. Methods: In this review we report the most recent studies demonstrating the beneficial effects of GLP-1RAs on renal outcomes, and also discuss the direct and indirect mechanisms through which they confer kidney protection. Finally, we discuss the metabolic and anti-inflammatory effects of GLP-1RAs in diabetic patients with COVID-19 disease. Results: GLP-1RAs have a nephroprotective action, which is expressed through both indirect (improvement of blood pressure and glycaemic control, weight loss) and direct (restoration of normal intrarenal haemodynamics, prevention of ischaemic and oxidative damage) effects. They have shown also metabolic and anti-inflammation beneficial effects in patients with COVID-19 disease. Conclusions: GLP-1RAs prevent albuminuria and slow the decline of renal function towards end stage renal disease in patients with diabetic kidney disease. They might be an opportunity to break the typical inflammation processes of COVID-19 disease.

Overview

CoChat Summary

TL;DR

GLP-1 receptor agonists appear nephroprotective in type 2 diabetes and diabetic kidney disease through indirect effects on blood pressure, glycaemic control and weight, plus direct effects on intrarenal haemodynamics and ischaemic/oxidative damage. They reduce albuminuria and slow renal function decline, though evidence for hard renal endpoints is mixed and further trials are needed.

Key findings

  • GLP-1RAs reduce albuminuria and slow the decline of renal function toward end-stage renal disease in patients with diabetic kidney disease, via indirect and direct mechanisms.
  • In LEADER (9340 patients, mean follow-up 3.8 years), liraglutide lowered nephropathy incidence by 22% versus placebo, mainly through favourable effects on macroalbuminuria, with slower eGFR decline in moderate/severe CKD.
  • In SUSTAIN-6 (3297 patients, 2.1 years), semaglutide reduced onset/worsening of nephropathy (3.8% versus 6.1%) and macroalbuminuria by up to 46%, but showed no difference in ESRD or renal death.
  • In AWARD-7 (577 patients with CKD G3/G4, 52 weeks), dulaglutide attenuated eGFR decline versus insulin glargine (−1.1, −1.5 and −2.9 mL/min/1.73 m² in the three groups), with no statistically significant UACR difference.

Methods

  • Narrative review of recent studies on GLP-1RA pharmacokinetics/pharmacodynamics, direct and indirect nephroprotective mechanisms, renal outcomes in diabetic patients, and metabolic/anti-inflammatory effects in COVID-19.
  • Summarizes randomized controlled trials including LEADER, SCALE, LIRA-RENAL, SUSTAIN, ELIXA, EXSCEL, AWARD-7 and REWIND, plus meta-analyses and guidelines; Table 1 lists renal endpoints and results.
  • No systematic review methods, primary data collection, or formal risk-of-bias assessment are described.

Limitations

  • The paper states that mechanisms of nephroprotection are poorly understood, clinical use remains limited, high cost is an important limitation for first-line use, and further studies are needed to expand knowledge and long-term cardiovascular/renal outcomes.
  • The paper notes that LIRA-RENAL’s neutral result could be partly due to its small sample size and short observation period.
  • Evident from the text: this is a narrative review relying on selected trials and post-hoc/exploratory analyses, and the FLOW trial results were still pending, expected in 2024.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ckj/sfac069

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1: Physiologic effects of GLP-1 (adapted from Granata et al. [11]).
Figure 1: Physiologic effects of GLP-1 (adapted from Granata et al. [11]).CC BY-NC · PubMed Central
Figure 2: Direct and indirect effects through which GLP-1RAs confer nephroprotection (adapted from Granata et al. [11]).
Figure 2: Direct and indirect effects through which GLP-1RAs confer nephroprotection (adapted from Granata et al. [11]).CC BY-NC · PubMed Central

Verification

Claims the paper makes

6 Valid · 3 Not valid · 45 Not checked · 34 Own results and interpretations

50 more claims · 1 with their cited sources checked

Create a free account to see all 88 claims and to verify the 66 references still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Tuttle, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/nejmoa1612917 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S.
Affiliations
  • Ospedale Cannizzaro (IT)
  • University of Catania (IT)
  • University of Bari Aldo Moro (IT)
  • University of Palermo (IT)
Corresponding author
Maccarrone, Rosario
Venue
Clinical Kidney Journal
Published
2022-03-12
Volume
15
Issue
9
Pages
1657-1665
ISSN
  • 2048-8505 (ISSN-L)
  • 2048-8513
OpenAlex
W4214865414
Cited by
54
References
67
Citations by year
2026: 10 · 2025: 16 · 2024: 21 · 2023: 5 · 2022: 2
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Clinical Kidney Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
GLP-1 receptor agonists, diabetic nephropathy, type 2 diabetes, renal protection, albuminuria, end-stage renal disease, renal function decline, oxidative stress, COVID-19 pandemic, anti-inflammatory activity, glycemic control, weight loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. https://app.cochat.ai/papers/10.1093/ckj/sfac069
The paper
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022). GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfac069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.